The Sangamo trial uses synthetic RNA interference (siRNAi).
This is much less effective than Calimmune's approach which uses the long lasting (probably permanent) shRNAi or by its other name ddRNAi.
In cancer trials the ddRNAi approach is getting better results than the synthetic trials.
Look into the FANG trials that Gradalis are doing. They have cured many terminal patients in early trials.
